To Help Maximize the Safety and Availability of Plasma, CERUS Partnered with POREX
CERUS partnered with POREX to supply components for the inactivation of pathogens in platelets and plasma. The INTERCEPT™ Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT™ treatment is designed to inactivate established transfusion threats including Hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, Malaria and Dengue. Patients around the world rely on INTERCEPT™ Blood System. POREX consistently delivers the quantities with the quality and time-frame required.
CERUS partnered with POREX to develop a technology that would be compatible with its system. The two organizations share a passion and commitment to making blood safer.
At POREX, we form partnerships with our customers, so we can fully understand their challenges and requirements. We develop innovative porous solutions that help make new products or take existing products and create ways for them to perform more effectively. We do this by providing functional porous components that can wick, vent, filter, diffuse, absorb and apply.
The POREX technology has been an integral part of the INTERCEPT™ System since it was launched. To date, approximately 5 million transfusable doses have been produced. The INTERCEPT™ technology reduces the risk for patients from having septic transfusion reactions and infectious disease complications. The product has a positive impact on thousands of patients each day and has demonstrated that it saves lives. CERUS currently markets and sells the INTERCEPT™ Blood System for platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.